Susan Altschuller's most recent trade in Mural Oncology plc was a trade of 10,000 Ordinary Shares done at an average price of $3.2 . Disclosure was reported to the exchange on Aug. 14, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Mural Oncology plc | Susan Altschuller | Director | Purchase of securities on an exchange or from another person at price $ 3.21 per share. | 14 Aug 2024 | 10,000 | 10,000 | - | 3.2 | 32,071 | Ordinary Shares |
| Mural Oncology plc | Susan Altschuller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 8,462 | 8,462 | - | - | Stock Option (right to buy) | |
| Mural Oncology plc | Susan Altschuller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 8,462 | 8,462 | - | - | Stock Option (right to buy) | |
| Cerevel Therapeutics Holdi... | Altschuller Susan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 81,065 | 81,065 | - | - | Restricted Stock Units | |
| Cerevel Therapeutics Holdi... | Susan Altschuller | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2023 | 30,721 | 0 | - | - | Restricted Stock Units | |
| Cerevel Therapeutics Holdi... | Susan Altschuller | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2023 | 30,721 | 30,721 | - | - | Common Stock | |
| Cerevel Therapeutics Holdi... | Susan Altschuller | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 41.42 per share. | 19 Dec 2023 | 13,808 | 16,913 | - | 41.4 | 571,972 | Common Stock |
| Mural Oncology plc | Susan Altschuller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2023 | 15,021 | 15,021 | - | - | Stock Option (right to buy) | |
| Cerevel Therapeutics Holdi... | Susan Altschuller | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 124,168 | 124,168 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdi... | Susan Altschuller | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 30,721 | 30,721 | - | - | Restricted Stock Units | |
| Immunogen, Inc. | Susan Altschuller | SVP AND CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2022 | 82,500 | 123,750 | - | - | Stock Option (Right to Buy) | |
| Immunogen, Inc. | Susan Altschuller | SVP AND CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2022 | 41,250 | 41,250 | - | - | Stock Option (Right to Buy) | |
| Immunogen, Inc. | Susan Altschuller | SVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 361,568 | 361,568 | - | - | Common Stock (right to buy) | |
| Immunogen, Inc. | Susan Altschuller | SVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 163,798 | 163,798 | - | - | Common Stock (right to buy) | |
| Immunogen, Inc. | Susan Altschuller | SVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2020 | 300,000 | 300,000 | - | - | Common Stock (right to buy) |